Market Place
Sourcing Support
NICE Draft Backs Amivantamab Combo for EGFR Exon 20 NSCLC
08 May 2026 //
FIRSTWORD PHARMA
CAPLYTA Tops Adjunctive MDD Treatments in New Meta-Analysis
04 May 2026 //
PR NEWSWIRE
Nanobiotix Amends Global Phase 3 Head/Neck Cancer Protocol
04 May 2026 //
GLOBENEWSWIRE
J&J Discontinues 2 CAR-T Lymphoma Therapies Due To Market Changes
01 May 2026 //
ENDPOINTS
Senzime Strengthens U.S. Operations With New Leadership
29 Apr 2026 //
PHARMIWEB
FDA Grants Priority Review for Nipocalimab in wAIHA
27 Apr 2026 //
PR NEWSWIRE
FDA Approves CAPLYTA sNDA for Relapse Risk in Schizophrenia
27 Apr 2026 //
PR NEWSWIRE
J&J to Join Bernstein`s 42nd Annual Strategic Decisions Event
27 Apr 2026 //
BUSINESSWIRE
J&J Puts Blockbuster Blood Thinner Xarelto On Trumprx
27 Apr 2026 //
BIOSPACE
J&J Sees AI Halving The Time To Generate Drug Development Leads
27 Apr 2026 //
REUTERS
Johnson & Johnson to offer four prescription medicines on TrumpRx
27 Apr 2026 //
REUTERS
Johnson & Johnson Offers Four Prescription Medicines On Trumprx
24 Apr 2026 //
REUTERS HEALTHCARE
IMAAVY Shows 2-Year Control in Generalized Myasthenia Gravis
23 Apr 2026 //
GLOBENEWSWIRE
J&J Earns CE Mark for New ETHICON 4000 Stapler
22 Apr 2026 //
BUSINESSWIRE
J&J to Join 2026 RBC Capital Markets Healthcare Conference
21 Apr 2026 //
BUSINESSWIRE
Bayer falls short in bid to block J&J’s survival claims
20 Apr 2026 //
FIERCE PHARMA
U.S. Judge Rejects Bayer Bid to Block J&J Cancer Claims
19 Apr 2026 //
FIRSTWORD PHARMA
Meiragtx Acquires Eye Disease Gene Therapy From J&J After Trial
16 Apr 2026 //
BIOSPACE
J&J hands back failed gene therapy to MeiraGTx
16 Apr 2026 //
FIERCE BIOTECH
J&J to Participate in Bank of America 2026 Healthcare Conference
15 Apr 2026 //
BUSINESSWIRE
J&J Reports Q1 2026 Results, Lifts Full-Year Outlook
14 Apr 2026 //
BUSINESSWIRE
J&J Marks 64th Straight Year of Dividend Growth, Up 3.1%
14 Apr 2026 //
BUSINESSWIRE
J&J Charts Speedy Launch Of New Psoriasis Pill Icotyde
14 Apr 2026 //
FIERCE PHARMA
J&J Targets $100B Revenue by 2026 After Strong Q1
14 Apr 2026 //
BIOSPACE
J&J Showcases Clinical Data for TECNIS PureSee IOL at ASCRS 2026
10 Apr 2026 //
BUSINESSWIRE
J&J, Royalty To Co-Fund $500M Autoimmune Antibody Program
30 Mar 2026 //
FIERCE BIOTECH
Nanobiotix Presents Ph2 Data JNJ-1900 Stage 3 Lung Cancer
30 Mar 2026 //
GLOBENEWSWIRE
J&J`s Impella Pumps Miss The Mark In 2 Major PCI Studies
30 Mar 2026 //
FIERCE BIOTECH
Takeda Clears Path To FDA With Phase 3 Data On $4B Psoriasis Bet
28 Mar 2026 //
FIERCE BIOTECH
ICOTYDE Shows 1-Year Efficacy & Safety in Plaque Psoriasis
28 Mar 2026 //
PR NEWSWIRE
New SPRAVATO Data: Robust Effects in Real-World TRD
28 Mar 2026 //
GLOBENEWSWIRE
J&J DARZALEX First Self-Admin Oncology Injectable Approved
27 Mar 2026 //
GLOBENEWSWIRE
Pharma R&D Spend Decreases By 3.6% Amid Pipeline Prioritization
25 Mar 2026 //
BIOSPACE
Dizal`s Zegfrovy Adds More Pressure To J&J`s Rybrevant
23 Mar 2026 //
FIERCE PHARMA
J&J Leads Pharma Revenue; Lilly Surges With Obesity Sales
18 Mar 2026 //
BIOSPACE
US FDA Approves J&J`s Oral Psoriasis Pill
18 Mar 2026 //
REUTERS
J&J Changes New York State Of Mind, Closing JLABS Site
17 Mar 2026 //
FIERCE BIOTECH
Johnson & Johnson Drives Innovation In Pulsed Field Ablation
16 Mar 2026 //
BUSSINESSWIRE
Monte Rosa Therapeutics Secures Supply Deal For MRT-2359 Phase 2
16 Mar 2026 //
GLOBENEWSWIRE
J&J Alleges Trade Secret Theft By Former Staffer Linked To Summit
16 Mar 2026 //
FIERCE PHARMA
J&J highlights promising first-in-human Erda-iDRS results
13 Mar 2026 //
PR NEWSWIRE
Johnson & Johnson Announces FDA Approval Of TECNIS Puresee
12 Mar 2026 //
BUSSINESSWIRE
Legend Sloughs Off Carvykti Threat From J&J`s Tecvayli
12 Mar 2026 //
FIERCE PHARMA
J&J Chief Joaquin Duato Collects Sizable Pay Raise For 2025
11 Mar 2026 //
FIERCE PHARMA
Janssen Submits TECVAYLI to EMA for R/R Multiple Myeloma
10 Mar 2026 //
GLOBENEWSWIRE
EC approves AKEEGA for the treatment mHSPC Prostate Cancer
09 Mar 2026 //
GLOBENEWSWIRE
J&J Secures Third FDA Approval For Multiple Myeloma Treatment
07 Mar 2026 //
BIOSPACE
Johnson & Johnson Gets FDA Nod For TECVAYLI With DARZALEX
06 Mar 2026 //
PR NEWSWIRE
US FDA Approves Johnson & Johnson`s Blood Cancer Drug
05 Mar 2026 //
REUTERS
Johnson & Johnson to Host Investor Conference Call on Q1 Results
02 Mar 2026 //
BUSINESSWIRE
Johnson & Johnson Reports Promising Antitumor Activity
26 Feb 2026 //
PR NEWSWIRE
GSK Props Up Its Cabenuva In Adolescents With Long-Term Data
26 Feb 2026 //
FIERCE PHARMA
Johnson & Johnson Seeks FDA Approval For IMAAVY In wAIHA Anemia
25 Feb 2026 //
PR NEWSWIRE
EC Approves SC RYBREVANT for EGFR NSCLC Cancer
24 Feb 2026 //
PHARMIWEB
Bayer Sues J&J Over `Deeply Flawed` Erleada Promotional Claims
23 Feb 2026 //
FIERCE PHARMA
Guselkumab Maintains Ulcerative Colitis Remission For 3 Years
21 Feb 2026 //
PR NEWSWIRE
Rybrevant Faspro Earns FDA Breakthrough Therapy Designation
19 Feb 2026 //
PHARMIWEB
FDA Untitled Letter Lambastes Claims In Ad For J&J`s Tremfya
19 Feb 2026 //
FIERCE PHARMA
EMA Seeks Input On Drafting Myasthenia Gravis Trial Guide
19 Feb 2026 //
RAPS
J&J Halts Enrollment in Trial of AC Immune Alzheimer`s drug
19 Feb 2026 //
FIERCE BIOTECH
